EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53

Verna Cheung iD, Marta Davidson, Eshetu G Atenafu iD, Andrea Arruda, Jaime O Claudio, Aniket Bankar, Dawn Maze, Vikas Gupta, Hassan Sibai iD

Current Oncology · 12.07.2026 · 33 (7) · 419

DOI: 10.3390/curroncol33070419 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 12.07.2026. Verfasst von Verna Cheung und 8 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada. Hauptthemen laut MEDLINE: Mutation, Tumor Suppressor Protein p53, Myeloproliferative Disorders. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prognostic significance of myelodysplasia-related gene mutations (MDS-RGMs), defined by the ELN 2022 classification and Mutation-Enhanced International Prognostic Score System high-risk mutations (MIPSS70-HRM), in accelerated-phase (AP) and blast-phase (BP) myeloproliferative neoplasms (MPNs) remains unclear. We conducted a retrospective study of 101 AP/BP MPN patients with intermediate-risk cytogenetics, excluding TP53 mutations and adverse-risk karyotypes. We evaluated whether MDS-RGM or MIPSS70-HRM predicted treatment response, overall survival (OS), or disease-free survival (DFS) and whether treatment intensity affected OS. Patients included AP (29.7%) and BP (70.3%), with 55% receiving intensive therapy. Allogeneic stem cell transplant (ASCT) significantly improved OS (HR 0.31, 95% CI 0.19–0.50; p < 0.0001), as did AP versus BP at transformation (HR: 0.43, 95% CI 0.26–0.73; p = 0.0016). Among patients ≤ 70 years with ECOG 0–1 (N = 77), ASCT and reversion to chronic-phase MPN (cMPN) were associated with longer OS (p < 0.0001 and p = 0.0475). Treatment intensity alone did not significantly affect OS (p = 0.1991).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutationTumor Suppressor Protein p53Myeloproliferative DisordersHumansFemaleMaleRetrospective StudiesMiddle AgedAgedKaryotypeAdultPrognosis

Stichwörter der Autor:innen

high-risk mutationsmyeloproliferative neoplasmtreatment intensity

Substanzen

Tumor Suppressor Protein p53TP53 protein, human

Autor:innen und Institutionen

  • Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
  • Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON M5T 1P8, Canada.
  • Department of Biostatistics, University Health Network, Toronto, ON M5G 1X6, Canada.
  • Division of Biostatistics, DLSPH, University of Toronto, Toronto, ON M5T 3M7, Canada.

ORCID-Profile: Verna Cheung, Eshetu G Atenafu, Hassan Sibai

Zitieren

APA

Cheung, V., Davidson, M., Atenafu, E. G., Arruda, A., Claudio, J. O., Bankar, A., Maze, D., Gupta, V., & Sibai, H. (2026). Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53. Current Oncology, 33(7), 419. https://doi.org/10.3390/curroncol33070419

Vancouver

Cheung V, Davidson M, Atenafu EG, Arruda A, Claudio JO, Bankar A, et al. Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53. Current Oncology. 2026;33(7):419. doi:10.3390/curroncol33070419

BibTeX
@article{Cheung2026,
  author = {Cheung, Verna and Davidson, Marta and Atenafu, Eshetu G and Arruda, Andrea and Claudio, Jaime O and Bankar, Aniket and Maze, Dawn and Gupta, Vikas and Sibai, Hassan},
  title = {Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {7},
  pages = {419},
  doi = {10.3390/curroncol33070419}
}
Kostenlos starten →